Difference between revisions of "IPS implementationguide 2"
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
<div class="online-document-information"> | <div class="online-document-information"> | ||
| − | + | <div class="col-md-12"> | |
| − | + | <div class="panel panel-warning-white-border"> | |
| − | + | <div class="panel-heading"> | |
| − | + | <span class="panel-title"><i class="fa fa-cogs"/>Continuous Build </span> | |
| − | + | </div> | |
| − | + | <div class="panel-body"> | |
| − | + | <p class="bs">This is the '''Continuous Build''' of the HL7 CDA® R2 Implementation Guide '''International Patient Summary''' (will be incorrect/inconsistent at times).</p> See the [http://www.hl7.org/implement/standards/product_brief.cfm?product_id=483 Directory of the published standard]. </div> | |
| − | + | </div> | |
| − | + | </div> | |
</div> | </div> | ||
Revision as of 12:39, 6 August 2024
Continuous Build
This is the Continuous Build of the HL7 CDA® R2 Implementation Guide International Patient Summary (will be incorrect/inconsistent at times).
See the Directory of the published standard. Document Information
This document contains: Standard for Trial Use International Patient Summary (2.00). The text materials belong to category cdaips.
CDAR2_INTLPATSUMMARY_STU_R2_2024OSEP
HL7 CDA® R2 Implementation Guide
International Patient Summary
STU Release 2 (Universal Realm)
International Patient Summary
STU Release 2 (Universal Realm)
Standard for Trial Use
© 2024 Health Level Seven International ® ALL RIGHTS RESERVED. The reproduction of this material in any form is strictly forbidden without the written permission of the publisher. HL7 and Health Level Seven are registered trademarks of Health Level Seven International. Reg. U.S. Pat & TM Off.
Use of this material is governed by HL7's IP Compliance Policy.
